Lenalid 10 Capsule contains Lenalidomide 10 mg, an immunomodulatory agent indicated primarily for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Lenalidomide exerts its therapeutic effects by modulating the immune system, inhibiting angiogenesis, and inducing apoptosis of malignant cells. It is commonly prescribed as part of combination therapy or as monotherapy depending on the specific hematologic malignancy and patient profile. The capsule formulation allows for oral administration, facilitating ease of use and adherence. Lenalid 10 Capsule should be used under strict medical supervision due to potential adverse effects, including neutropenia, thrombocytopenia, thromboembolic events, and teratogenicity. Regular monitoring of blood counts and renal function is recommended during treatment. Patients are advised to adhere to pregnancy prevention programs because of the high risk of fetal harm. Dose adjustments may be necessary in cases of renal impairment or hematologic toxicity. Lenalid 10 Capsule is contraindicated in patients with hypersensitivity to Lenalidomide or any capsule components. This medication should be stored at controlled room temperature, protected from moisture and light. Consultation with a healthcare professional is essential before initiating therapy to ensure appropriate use and monitoring.